Health Care Down as Earnings, Risk Aversion Hurt Biotech -- Health Care Roundup
February 05 2018 - 5:06PM
Dow Jones News
Shares of health-care companies fell sharply as disappointing
earnings and a flight from risk weighed on biotechnology issues.
The iShares Nasdaq Biotech Index exchange-traded fund, a basket of
biotech stocks, fell by 4% and is down more than 10% since its peak
in January. Drug makers including Eli Lilly, have warned that they
may have difficulty raising prices, something that's of particular
concern to biotech companies whose products are often sold for very
high margins. There's also a growing concern among biotech
investors that "biosimilars," or generic versions of treatments,
will soon pose a threat to the most lucrative franchises. Shares of
Amgen fell by roughly 5%. Late last week, the biotech giant's
quarterly earnings were short of some investors' expectations,
reflecting relatively weak demand for some of its newer
treatments.
-Rob Curran, rob.curran@dowjones.com
(END) Dow Jones Newswires
February 05, 2018 16:51 ET (21:51 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024